From Our 2011 Archives

FDA Approves First Combo Drug for Diabetes, Cholesterol

FRIDAY, Oct. 7 (HealthDay News) -- A first-of-a-kind pill that treats both type 2 diabetes and high cholesterol was approved by the U.S. Food and Drug Administration on Friday.

Juvisync is a prescription medication that contains two previously approved medicines, sitagliptin (Januvia) and simvastatin (Zocor). Sitagliptin helps lower blood sugar levels, and simvastatin reduces the amount of "bad" low-density lipoprotein in the blood.

The Juvisync dosage strengths approved by the FDA are 100 milligrams (mg) of sitagliptin with 10 mg, 20 mg or 40 mg of simvastatin. The drug maker -- MSD International GmbH Clonmel, Co. of Ireland -- has promised to develop Juvisync doses with 50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg of sitagliptin/simvastatin, according to an FDA news release.

Patients who require a 50-mg dose of sitagliptin should continue to use single-ingredient sitagliptin tablets with that dose until Juvisync with 50 mg of sitagliptin is available, the FDA said.

"This is the first product to combine a type 2 diabetes drug with a cholesterol-lowering drug in one tablet," Dr. Mary H. Parks, director of the division of metabolism and endocrinology products in the FDA's Center for Drug Evaluation and Research, said in the news release.

"However, to ensure safe and effective use of this product, tablets containing different doses of sitagliptin and simvastatin in fixed-dose combination have been developed to meet the different needs of individual patients. Dose selection should factor in what other drugs the patient is taking," Parks added.

The most common side effects of Juvisync include: upper respiratory infection; stuffy or runny nose and sore throat; headache, muscle and stomach pain; constipation; and nausea.

Many of the estimated 20 million people in the United States with type 2 diabetes also have high cholesterol, the FDA researchers noted. The two conditions are associated with increased risk of chronic conditions, such as heart disease, stroke, kidney disease and blindness.

-- Robert Preidt

MedicalNewsCopyright © 2011 HealthDay. All rights reserved.

SOURCE: U.S. Food and Drug Administration, news release, Oct. 7, 2011




STAY INFORMED

Get the Latest health and medical information delivered direct to your inbox!